Amgen Inc. has announced positive topline results from the Phase 3 FORTITUDE-101 clinical trial, which evaluated the efficacy of bemarituzumab plus chemotherapy in patients with FGFR2b overexpression in first-line gastric cancer. The trial met its primary endpoint, showing a significant improvement in overall survival compared to chemotherapy alone. The most common adverse events in this treatment group included reduced visual acuity, punctate keratitis, and anemia among others. Detailed results from the study are set to be presented at a future medical meeting. Additionally, a Phase 3 study involving bemarituzumab, chemotherapy, and nivolumab is currently ongoing, with results expected in the second half of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。